Drug Trial Radar · NCT07699276
Steroid Sparing Regimen With Olanzapine and Palonosetron for Emetic Prevention for High Dose Cisplatin
Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
95
Planned (sponsor's estimate)
Start
Feb 10, 2026
Primary completion
Oct 1, 2027
Study completion Nov 15, 2027
Sponsor
- Lead sponsor
- Mahidol UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase II study evaluating dexamethasone sparing regimen with olanzapine and palonosetron for patients receiving high dose cisplatin to prevent chemotherapy induced nausea and vomiting
Conditions
- Cancer (Solid Tumors)
- Vomiting
- Cisplatin
- Olanzapine
Interventions
dexamethasone sparingDrug
omit dexamethasone on day 2-4
Primary outcomes
What the sponsor says the trial is designed to measure.
- complete response rateTime frame: 5 days after receiving chemotherapy
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Faculty of Medicine Siriraj Hospital, Mahidol University
Bangkok, Thailand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.